ADPT Adaptive Biotechnologies margins

Relative Growth: Rel. Growth: 62

Relative Strength: Rel. Strength: 91

Relative Valuation: Rel. Valuation: 7

Relative Profitability: Rel. Profitability: 41

Gross margin

75.6%

Operating margin

-12.2%

EBITDA margin

-10%

Net margin

-20.7%

Adaptive Biotechnologies reports a gross margin of 75.6%, an operating margin of -12.2%, an EBITDA margin of -10%, and a net margin of -20.7%, while its operating margin is negative at -12.2%, its EBITDA margin is negative at -10%, and its net margin is negative at -20.7%. All measured margins increased year over year, led by operating margin with an increase of 46.8 percentage points.

ADPT margin history

Gross, operating, EBITDA and net margin trends

Over the last 3 years, Adaptive Biotechnologies's margins averaged 64.65% gross, -73.23% operating, -55.19% EBITDA, and -73.24% net. All four current margins are above their three-year averages.

ADPT margin expansion

Year-over-year margin changes in percentage points

All available margins expanded year over year, led by operating margin with an increase of 46.8 percentage points.

Gross margin expansion

9.6pp

Operating margin expansion

46.8pp

EBITDA margin expansion

31.9pp

Net margin expansion

38.4pp

ADPT Gross margin

Across the last 3 years, Adaptive Biotechnologies's gross margin came to 64.65%. The current gross margin stands at 75.6%, 11 percentage points above its three-year average. Gross margin was highest at 75.6% in Jun 2026 and lowest at 54.8% in Jun 2024.

ADPT Operating margin

Adaptive Biotechnologies's operating margin averaged -73.23% over the last 3 years. Currently, Adaptive Biotechnologies's current operating margin is -12.2%, which is 61 percentage points above its three-year average. Over the last 3 years, Adaptive Biotechnologies's operating margin peaked at -12.2% in Jun 2026 and reached a low of -133.3% in Dec 2023.

ADPT EBITDA margin

Across the last 3 years, Adaptive Biotechnologies's EBITDA margin averaged -55.19%. Adaptive Biotechnologies currently reports an EBITDA margin of -10%, 45.2 percentage points above its three-year average. EBITDA margin was highest at -5.2% in Mar 2026 and lowest at -107.1% in Dec 2023.

ADPT Net margin

Across the last 3 years, Adaptive Biotechnologies recorded an average net margin of -73.24%. Adaptive Biotechnologies's current net margin is -20.7% and is 52.5 percentage points above its three-year average. The highest net margin for Adaptive Biotechnologies was -16.8% in Mar 2026, while the lowest was -132.3% in Dec 2023.

ADPT margin group comparison

Margins compared with peer-group, industry and sector averages

With a gross margin of 75.6%, ADPT stands higher than the Healthcare sector average but lower than the industry average. Looking at the Healthcare sector average of 68.3%, Adaptive Biotechnologies's gross margin is 11% higher.

ADPT margin peer comparison

Compare margins with selected peers

Frequently asked questions

What is Adaptive Biotechnologies's gross margin?

For the period ending Jun 30, 2026, ADPT recorded a gross margin of 75.6%.

What is Adaptive Biotechnologies's operating margin?

The current operating margin for ADPT is -12.2% as of Jun 30, 2026.

What is Adaptive Biotechnologies's EBITDA margin?

As of Jun 30, 2026, ADPT has an EBITDA margin of -10%.

What is Adaptive Biotechnologies's net margin?

The current net margin for ADPT is -20.7% as of Jun 30, 2026.

What are the average margins of ADPT?

Looking back over 3 years, ADPT recorded average margins of 64.7% gross, -73.2% operating, -55.2% EBITDA, and -73.2% net.

What are the highest historical margins of ADPT?

In the last 5 years, the highest margins reported by ADPT were 75.6% gross in Jun 2026, -12.2% operating in Jun 2026, -5.2% EBITDA in Mar 2026, and -16.8% net in Mar 2026.

What are the lowest historical margins of ADPT?

In the last 5 years, the lowest margins reported by ADPT were 54.8% gross in Jun 2024, -149.3% operating in Mar 2022, -133.3% EBITDA in Mar 2022, and -148.4% net in Mar 2022.